Literature DB >> 8639781

Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

M Furlan1, R Robles, B Lämmle.   

Abstract

Proteolytic cleavage of von Willebrand factor (vWF) takes place in the circulating blood of healthy subjects and is increased in some patients with von Willebrand disease type 2A. The hemostatically active large vWF multimers are degraded to smaller less active forms. It has been suggested that the polypeptide subunit of vWF is cleaved at the peptide bond 842Tyr-843Met. We purified (approximately 10,000-fold) from human plasma a vWF-degrading protease, using chelating Sepharose, hydrophobic interaction chromatography, and gel filtration. The enzyme was found to be virtually absent in the platelet lysates obtained by repeated freezing and thawing. The proteolytic activity was associated with a high molecular weight protein (approximately 300 kD) as judged by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. vWF was resistant against the protease in a neutral buffer at physiological ionic strength but became degraded at low salt concentration or in the presence of 1 mol/L urea. No degradation of human fibrinogen, bovine serum albumin, of calf skin collagen by the purified protease was noted under the same experimental conditions. Proteolytic activity showed a pH optimum at 8 to 9 and was strongly inhibited by chelating agents, whereas only slow inhibition was observed with N-ethylmaleimide. There was no inhibition by iodoacetamide, leupeptin, or serine protease inhibitors. The best peptidyl diazomethyl ketone inhibitor was Z-Phe-Phe-CHN2. Activation by divalent metal ions was found to increase in the following order: Zn2+ approximately Cu2+ approximately CD2+ approximately Ni2+ approximately Co2+ <Mn2+ <Mg2+ <Ca2+ <Sr2+ <Ba2+. The observed properties of the vWF-degrading enzyme differ from those of all other hitherto described proteases. Purified vWF was incubated with the protease, and the degraded material subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis after disulfide reduction. The size, amino acid composition, and amino terminal sequence of the reduced fragments confirmed that the peptide bond 842Tyr-843Met had been cleaved, ie, the same bond that has been proposed to be cleaved in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639781

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  167 in total

Review 1.  Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  S L Allford; S J Machin
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

2.  A new name in thrombosis, ADAMTS13.

Authors:  J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

3.  Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.

Authors:  Svenja Lippok; Matthias Radtke; Tobias Obser; Lars Kleemeier; Reinhard Schneppenheim; Ulrich Budde; Roland R Netz; Joachim O Rädler
Journal:  Biophys J       Date:  2016-02-02       Impact factor: 4.033

4.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

5.  [Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].

Authors:  T Schmidt; D A Tsakiris; M Grapow; M Siegemund
Journal:  Anaesthesist       Date:  2010-12-25       Impact factor: 1.041

6.  von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.

Authors:  Anil K Chauhan; Janka Kisucka; Colin B Lamb; Wolfgang Bergmeier; Denisa D Wagner
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

7.  Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow.

Authors:  Zhenyin Tao; Yongtao Wang; Huiwei Choi; Aubrey Bernardo; Kenji Nishio; J Evan Sadler; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

8.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

9.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 10.  Diverse activities of von Willebrand factor in traumatic brain injury and associated coagulopathy.

Authors:  Xin Xu; Rosemary Kozar; Jianning Zhang; Jing-Fei Dong
Journal:  J Thromb Haemost       Date:  2020-10-06       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.